October 24, 2019 Clive Richardson Chief Executive Officer Akari Therapeutics Plc 75/76 Wimpole Street London W1G 9RT Re: Akari Therapeutics Plc Registration Statement on Form F-1 Filed October 15, 2019 File No. 333-234219 Dear Mr. Richardson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Gregory Dundas at (202) 551-3436 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Gary Emmanuel, Esq.